Biotherapeutics News and Research

RSS

Aptamer Group Ltd appoints Jordan Clark as Chief Commercial Officer

Aptamer Group, the developer of Optimer biotherapeutics and diagnostics, is pleased to announce the appointment of Jordan Clark as Chief Commercial Officer at Aptamer Group with immediate effect.

From Aptamer Group 10 Jun 2021

FDA approves new treatment for patients with hypoplasminogenemia

Today, the U.S. Food and Drug Administration approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type 1, also referred to as hypoplasminogenemia, a disorder that can impair normal tissue and organ function and may lead to blindness.

5 Jun 2021

Researchers report promising biotherapeutics for obesity and related medical complications

The research teams at the University of Hong Kong led by Professor Xuechen LI from the Research Division for Chemistry and Department of Chemistry, and Professor Yu WANG from the Department of Pharmacology and Pharmacy, reported a synthetic biotherapeutics with promising anti-tumor, insulin sensitising and hepatoprotective activities in the Journal of the American Chemical Society.

18 May 2021

Nanotechnology and COVID-19 diagnosis and treatment

The development of nano-biosensors and nanoparticle-based vaccines and medicines has opened a new path toward better management of the coronavirus disease 2019 (COVID-19) pandemic. In a recently published article in the journal ACS Biomaterials Science & Engineering, scientists have reviewed recent advancements in nanotechnology-based diagnostic and therapeutic interventions against human coronaviruses.

17 May 2021

Study reveals how oral antiviral drug works to attack SARS-CoV-2 virus

A University of Alberta virology lab has uncovered how an oral antiviral drug works to attack the SARS-CoV-2 virus, in findings published May 10 in the Journal of Biological Chemistry.

12 May 2021

Nanoscope presents optical gene delivery, OCT-guided electrophysiology platforms at ARVO annual meeting

Nanoscope Technologies LLC, a biotechnology company developing gene therapies for treatment of retinal diseases, is featuring multiple scientific presentations highlighting its groundbreaking research on optical gene delivery for vision restoration and OCT-guided electrophysiology platforms for characterization of retinal degeneration and assessment of efficacy of cell-gene therapy at the 2021 ARVO annual (virtual) meeting, May 1-7.

5 May 2021

Repairing faulty drains could be key to unlocking the potential of Alzheimer's therapies

Experimental Alzheimer's drugs have shown little success in slowing declines in memory and thinking, leaving scientists searching for explanations.

29 Apr 2021

NIH to conduct large trial for COVID-19 polyclonal antibody therapies

The National Institutes of Health (NIH) in the USA are to conduct a large-scale clinical trial to evaluate a new fully-human polyclonal antibody therapy targeted at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

23 Apr 2021

Experimental antiviral drug for COVID-19 shows effectiveness in hamster models

The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists.

17 Apr 2021

Gyros Protein Technologies introduces Gyrolab Bioaffy 4000 CD to extend sensitivity of immunoassay CD range

Gyros Protein Technologies AB today announced the introduction of Gyrolab® Bioaffy™ 4000 CD for immunoassay applications in biotherapeutic workflows.

From Gyros Protein Technologies AB 27 Jan 2021

New antiviral drug completely suppresses SARS-CoV-2 transmission within 24 hours

Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.

3 Dec 2020

Horizon Discovery licenses CHOSOURCE to Sanyou Biopharmaceuticals Co.

Horizon Discovery today announced that it has granted commercial licenses for its cGMP-compliant CHOSOURCE™ platform to Sanyou Biopharmaceuticals.

From Revvity 2 Dec 2020

Researchers successfully edit SIV virus from genomes of non-human primates

Taking a major step forward in HIV research, scientists at the Lewis Katz School of Medicine at Temple University have successfully edited SIV - a virus closely related to HIV, the cause of AIDS - from the genomes of non-human primates.

1 Dec 2020

Unique training program is bolstering Canada’s capacity to manufacture novel biotherapeutics

As COVID-19 highlights the urgent need to increase vaccine manufacturing around the world, a unique training program is bolstering Canada's capacity to manufacture vaccines, as well as viral immunotherapies for cancer and other emerging biotherapeutics.

23 Nov 2020

Lonza provides expansive selection of high-resolution HLA-typed primary cells to boost drug development

Lonza has announced that it now provides an expansive selection of high-resolution Human Leukocyte Antigen (HLA)-typed primary cells spanning all major cell and tissue types.

From Lonza 20 Nov 2020

Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer

Adaptate Biotherapeutics, a company focused on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced the appointment of Stewart Kay as Chief Business Officer.

28 Oct 2020

New DNA-cutting tool could advance gene editing for novel treatments

Gene editing for the development of new treatments, and for studying disease as well as normal function in humans and other organisms, may advance more quickly with a new tool for cutting larger pieces of DNA out of a cell's genome, according to a new study by UC San Francisco scientists.

21 Oct 2020

Novel microfluidic approach to fight cancer could greatly benefit patients

CAR-T biotherapeutics company Carina Biotech and researchers at the University of South Australia have developed a novel approach based on microfluidic technology to "purify" the immune cells of patients in the fight against cancer.

20 Oct 2020

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and esophageal cancers who currently have poor survival.

21 Sep 2020

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.

From Avacta Life Sciences Ltd. 8 Sep 2020